This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BG Medicine, Inc. Announces Publication Of Important Galectin-3 Study Designed To Identify Adults In General Population At Risk For Heart Failure

WALTHAM, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the study, "Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community," was published online in the current issue of the Journal of the American College of Cardiology 1 (JACC). The study, conducted by the National Heart, Lung, and Blood Institute's (NHLBI) Framingham Heart Study, was designed to determine whether elevated levels of galectin-3 in the population at large identify those who are at increased risk for the development of heart failure. Galectin-3 levels were measured in blood specimens collected from 1996-1998 as part of a routine examination of 3,353 participants enrolled in the NHLBI-supported Framingham Offspring Cohort. The study demonstrated that men and women with baseline blood levels of galectin-3 in the highest quartile had heart failure incidence rates that were more than twice as high as those of all other study participants, over a ten year follow-up period.

"Our research at Framingham represents the first U.S.- based large-scale study to examine whether elevated levels of galectin-3 in the population at large can identify people who may be at risk for development of heart failure," said Daniel Levy, M.D., Director, Framingham Heart Study, National Heart, Lung, and Blood Institute. "Galectin-3 is associated with cardiac fibrosis, which plays an important role in the development of heart failure, so it may be useful in identifying patients at high risk for heart failure prior to the onset of symptoms and could point the way to earlier prevention and treatment strategies."

"The results published in JACC emphasize the significance of being able to detect factors that impact the identification and progression of heart failure, as nearly one in six people in the general adult population may have elevated levels of galectin-3 and be at risk," said Eric Bouvier, President and CEO of BG Medicine. "As part of our corporate strategy to develop and commercialize cardiovascular diagnostics that address significant medical needs, we filed a 510(k) for an expanded indication for the BGM Galectin-3 ® test with the U.S. Food and Drug Administration (FDA) in May 2012, and have obtained CE Mark in Europe. Subject to FDA clearance, the new application would expand the indicated use of our galectin-3 test to the general adult population to identify those with elevated levels of galectin-3, which is associated with an increased risk for the development of new-onset heart failure."

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to carbohydrates called beta-galactosides. Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure, and is believed to be a primary mediator of progressive cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and adverse remodeling (changes in the structure of the heart). Heart failure affects an estimated 5.8 million Americans, with approximately 670,000 new cases occurring each year. The direct and indirect cost of heart failure in the United States for 2010 is estimated to be $39.2 billion.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs